osimertinib,lazertinib,amivantamab-vmjw
astrazeneca,yuhan corp,janssen,genmab
['lcsm,(-blcsm)', 'osimertinib', 'sclc', 'nsclc', 'chrysalis-2']
chrysalis-2 egfr mut nsclc 3rd line after osimertinib and chemo. orr in heavily pretreated 39%! ic-orr 26%. no new safety signals. will it fill the unmet need in the post-osi space? #asco22 #lcsm 
Thoracic Med Onc @MUSChealth @muschollings Charleston, South Carolina. Former Heme/Onc fellow @MontefioreNYC @EinsteinMed